Russian Pharmaceutical Industry Leader
01.06.2020
Adezmapimod – a New Name in the World Pharmaceutical Industry
Adezmapimod – a New Name in the World Pharmaceutical Industry

The World Health Organization has assigned an International Nonproprietary Name “Adezmapimod” to the pharmaceutical substance of Seroguard®, the innovator drug developed by the Pharmasyntez Group under the State Program PHARMAMED. 

The drug is intended to reduce the risk of adhesions and prevent adhesions following open and laparoscopic abdominal surgery. It is primarily intended for use in abdominal surgery and gynecology and has no analogues in the world. The developers estimate that the drug has a high export potential and will be in demand not only in the Russian Federation and the CIS countries, but also in Europe and on the American continent, especially in the US market, the volume of which is estimated to be $1.4 billion a year. Pharmasyntez has received 28 patents for the product that are valid in 103 countries throughout the world. 

Seroguard® is a potentially breakthrough drug in the prophylaxis of adhesive disease that causes numerous complications every year, including life-threatening ones, and results in repeat surgical interventions. 

Adezmapimod will be included in the list of 124 INNs assigned by the World Health Organization in 2020 and will be published in WHO Drug Information by June 25, 2020. 

For reference: Assigning an INN to a pharmaceutical substance is the highest criterion of recognition by the international expert community of an innovative drug created by a particular developer and allows objective assessment of the contribution of different countries to the global health system.